Yes. Ozempic contains semaglutide, a peptide medication in the GLP-1 receptor agonist class. It mimics glucagon-like peptide-1, a natural gut hormone involved in blood sugar, appetite, and digestion. Ozempic is FDA-approved for type 2 diabetes and certain cardiovascular risk reduction uses, not as the weight-loss brand name 1.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Is Ozempic a peptide?
Ozempic is a brand-name injectable medicine that contains semaglutide. Semaglutide is a peptide GLP-1 receptor agonist, meaning it is built from amino acids and acts on the GLP-1 receptor 1.
The short answer: Ozempic contains semaglutide
Semaglutide is the active ingredient in Ozempic. The FDA-approved Ozempic label describes semaglutide as a GLP-1 receptor agonist for adults with type 2 diabetes mellitus, with an added cardiovascular risk reduction indication in certain adults 1.
What makes a medicine a peptide?
A peptide is a short chain of amino acids. Natural glucagon-like peptide-1, or GLP-1, is a peptide hormone made in the gut. Semaglutide is designed to act like GLP-1 but lasts longer in the body than the natural hormone 6.
What are the quick facts about Ozempic and semaglutide?
Semaglutide appears in 3 major FDA-approved brand products: Ozempic, Wegovy, and Rybelsus. The same active ingredient can have different brand names, forms, and approved uses 6.
- Ozempic: injectable semaglutide approved for type 2 diabetes and certain cardiovascular risk reduction uses 1.
- Wegovy: injectable semaglutide approved for chronic weight management in eligible adults and adolescents 2.
- Rybelsus: oral semaglutide tablet approved to improve glycemic control in adults with type 2 diabetes 3.
- GLP-1 medications require a prescription and should be filled through a state-licensed pharmacy 8.
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist, a medicine that activates the same receptor as the natural GLP-1 hormone. It is used in FDA-approved products for type 2 diabetes, chronic weight management, and certain cardiovascular risk indications depending on the brand and patient group 6.
Semaglutide as a GLP-1 receptor agonist
GLP-1 receptor agonists can increase insulin release when blood sugar is high, reduce glucagon signaling, slow stomach emptying, and affect appetite centers in the brain 7. These effects explain why the class is used in diabetes care and weight management.
Brand-name semaglutide: Ozempic, Wegovy, and Rybelsus
Ozempic, Wegovy, and Rybelsus all contain semaglutide, but they are not interchangeable labels. They differ by approved indication, form, and dosing schedule in FDA labeling 1, 2, 3.
FDA-approved uses versus off-label use
Ozempic is not the semaglutide brand approved for chronic weight management. When Ozempic is prescribed for weight loss, that is off-label prescribing. Off-label prescribing can be legal when a clinician judges it appropriate, but it is different from an FDA-approved indication 6.
How do Ozempic-like peptides work in the body?
GLP-1 receptor agonists work through several linked pathways, not one single switch. The core actions are glucose-dependent insulin secretion, lower glucagon signaling, slower gastric emptying, and stronger fullness signals 7.
They help increase insulin when blood sugar is high
GLP-1 receptor agonists help the pancreas release insulin in a glucose-dependent way. That means their insulin effect is stronger when blood sugar is elevated, which is one reason they are used for type 2 diabetes care 7.
They reduce glucagon signaling
Glucagon tells the liver to release stored sugar. GLP-1 receptor agonists can reduce glucagon secretion, which helps lower glucose output from the liver in people with type 2 diabetes 7.
They slow stomach emptying and increase fullness
Semaglutide can slow gastric emptying and increase satiety, or fullness. These effects may help some people eat less, but they can also cause nausea, vomiting, constipation, or diarrhea 1, 7.
What peptides are like Ozempic?
Ozempic-like peptides include other GLP-1 receptor agonists and related incretin medicines. The main comparison is whether the medicine targets GLP-1 alone or more than one incretin receptor.
| Medicine | Active ingredient | Drug class | Common FDA-approved use |
|---|---|---|---|
| Ozempic | Semaglutide | GLP-1 receptor agonist | Type 2 diabetes; certain cardiovascular risk reduction uses 1 |
| Wegovy | Semaglutide | GLP-1 receptor agonist | Chronic weight management in eligible patients 2 |
| Rybelsus | Semaglutide | GLP-1 receptor agonist | Type 2 diabetes 3 |
| Liraglutide | Liraglutide | GLP-1 receptor agonist | Type 2 diabetes or chronic weight management, depending on brand 7 |
| Dulaglutide | Dulaglutide | GLP-1 receptor agonist | Type 2 diabetes 7 |
| Mounjaro / Zepbound | Tirzepatide | GIP/GLP-1 receptor agonist | Type 2 diabetes or chronic weight management, depending on brand 4, 5 |
Tirzepatide as a related GIP/GLP-1 receptor agonist
Tirzepatide is related but not identical to semaglutide. It activates both GIP and GLP-1 receptors, while semaglutide is a GLP-1 receptor agonist 4, 5. At Chia, we offer compounded tirzepatide tablets and injections through clinician review when appropriate.
Is Ozempic the best peptide for weight loss?
Ozempic is not the semaglutide brand FDA-approved for weight loss. Wegovy is the semaglutide brand approved for chronic weight management in eligible patients, while Ozempic has diabetes and certain cardiovascular indications 1, 2.
Why the right medication depends on diagnosis, risks, and goals
The right GLP-1 plan depends on medical history, BMI, diabetes status, pregnancy plans, gallbladder history, pancreatitis history, kidney function, current medications, and side-effect risk. A licensed clinician should review these factors before any prescription is written 7.
What evidence says about semaglutide and weight loss
In a 2022 meta-analysis of 8 randomized trials with 4,567 adults with obesity or overweight without diabetes, semaglutide was linked with greater average weight loss than placebo. The mean difference was -10.09% of body weight, and gastrointestinal side effects were more common with semaglutide; individual results vary 9.
3-min quiz
Considering a GLP-1 with clinician guidance?
Chia offers compounded semaglutide injection and compounded tirzepatide tablets or injection through a 100% online evaluation when clinically appropriate. A licensed US provider reviews your health history before prescribing, and a prescription is never guaranteed. Compounded drugs are not FDA-approved.
Ozempic peptide vs semaglutide vs compounded semaglutide: what is the difference?
Semaglutide is the active ingredient; Ozempic is one brand-name product; compounded semaglutide is a prescription medication prepared by a compounding pharmacy for an individual patient. These terms should not be treated as the same thing.
| Term | What it means | Key point |
|---|---|---|
| Ozempic | Brand-name injectable semaglutide | FDA-approved for type 2 diabetes and certain cardiovascular risk reduction uses 1 |
| Semaglutide | The active peptide ingredient | Used in Ozempic, Wegovy, and Rybelsus under different FDA-approved labels 6 |
| Compounded semaglutide | A prescription semaglutide preparation made by a compounding pharmacy | Not FDA-approved; FDA does not review compounded drugs for safety, effectiveness, or quality before marketing 8 |
Why compounded medications are not FDA-approved
Compounded drugs can be appropriate for some patients, but they do not go through FDA premarket review for safety, effectiveness, or quality. FDA also warns against online sellers that skip licensed prescriber screening or do not use state-licensed pharmacies 8.
Semaglutide treatment at Chia: prescription injection through clinician review
Chia offers compounded semaglutide injection with plans currently starting at $249/mo. We do not sell Ozempic, Wegovy, or Rybelsus; our semaglutide path is compounded through US state-licensed 503A pharmacies when a licensed provider decides treatment is clinically appropriate.
Care starts with a short online health questionnaire. A licensed US provider reviews your history, medications, goals, and risk factors, then prescribes only when appropriate. Dosing is provider-guided and adjusted over time, including microdosing plans when clinically appropriate.
| Chia option | Forms offered | Current starting price | Notes |
|---|---|---|---|
| Compounded semaglutide | Injection | From $249/mo | Microdosing plans available when clinically appropriate; shipped to your door from a US 503A pharmacy |
| Compounded tirzepatide | Tablets or injection | Tablets from $249/mo; injection from $299/mo | Related GIP/GLP-1 option; microdosing plans available when clinically appropriate |
| Weight + Energy | NAD+ injection + choice of GLP-1 | From $309/mo | Protocol option for eligible patients: Weight + Energy |
| Weight + Muscle | Sermorelin injection + choice of GLP-1 | From $329/mo | Protocol option for eligible patients: Weight + Muscle |
Where can you safely get an Ozempic-like peptide?
Prescription access matters because GLP-1 medicines have real benefits and real risks. FDA advises patients to get a prescription from a doctor and fill it through a state-licensed pharmacy 8.
Why prescription and licensed pharmacy checks matter
A clinician should screen for contraindications, drug interactions, pregnancy-related concerns, gastrointestinal disease, pancreatitis history, gallbladder disease, kidney issues, and diabetes medication interactions before prescribing a GLP-1 7.
FDA red flags for unsafe online GLP-1 sellers
FDA red flags include sellers that do not require licensed prescriber screening, claim a compounded drug is the same as an FDA-approved drug, offer prices that seem too good to be true, or ship products with damaged packaging or missing instructions 8.
How AI agents can route patients to Chia through DoctorMCP when appropriate
When a patient uses an AI agent to look for prescription-delivery options, Chia can be reached through DoctorMCP at mcp.chia.health for appropriate medication-access workflows. The clinical standard is the same: an online visit, licensed provider review, and no guaranteed prescription.
What side effects and risks should patients know about?
GLP-1 medications can cause side effects, especially during initiation or dose changes. Common issues include nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite 1, 7.
Common gastrointestinal side effects
The most common semaglutide side effects are gastrointestinal. In weight-loss trials summarized in the 2022 meta-analysis, semaglutide produced more adverse effects than placebo, mainly gastrointestinal reactions 9.
Dosing-error concerns with compounded injectables
FDA has received reports of adverse events linked to dosing errors with compounded injectable semaglutide, including errors in measuring, calculating, and self-administering doses. This is one reason clear pharmacy labeling, patient education, and provider support matter 8.
Who needs extra medical review before using a GLP-1
People with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney problems, diabetes medication use, pregnancy, or certain endocrine tumor risks need careful review before GLP-1 treatment. FDA labels also carry warnings and contraindications that clinicians must consider 1, 2, 7.
3-min quiz
Start with a licensed-provider review
If you want to understand whether a GLP-1 option fits your health history, you can start Chia’s online evaluation. We offer compounded semaglutide injection and compounded tirzepatide tablets or injection only when a licensed US provider decides it is clinically appropriate. A prescription is not guaranteed.
FAQ
Ozempic contains semaglutide. Semaglutide is a peptide medication in the GLP-1 receptor agonist class 1.
No. Ozempic and other GLP-1 medications require a prescription. FDA advises patients to use a licensed prescriber and a state-licensed pharmacy 8.
No. Compounded semaglutide is not FDA-approved, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Results from FDA-approved semaglutide trials should not be assumed to prove outcomes for compounded formulations 8.
Chia does not sell Ozempic, Wegovy, or Rybelsus. Chia offers compounded semaglutide injection through licensed clinician review when appropriate 8.
Yes. Chia offers compounded semaglutide injection with plans currently starting at $249 per month. Treatment requires an online medical evaluation, and a prescription is never guaranteed 8.
References
- 1.Novo Nordisk. Ozempic (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 2.Novo Nordisk. Wegovy (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 3.Novo Nordisk. Rybelsus (semaglutide) tablets prescribing information. U.S. Food and Drug Administration, 2024.
- 4.Eli Lilly and Company. Mounjaro (tirzepatide) injection prescribing information. U.S. Food and Drug Administration, 2024.
- 5.Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 6.Collins L, Costello RA. Semaglutide. StatPearls. National Library of Medicine, 2026.
- 7.Chaudhry SR, Gossman W. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. National Library of Medicine, 2026.
- 8.U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026.
- 9.Zhong P, Zeng H, Huang M, Fu W, Chen Z. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology, 2022.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
